Keros Therapeutics Inc
KROS21.030USD
-0.330-1.54%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
854.49MMarket Cap
13.21P/E TTM
More Details of Keros Therapeutics Inc Company
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Keros Therapeutics Inc Info
Ticker SymbolKROS
Company nameKeros Therapeutics Inc
IPO dateApr 08, 2020
CEOSeehra (Jasbir)
Number of employees169
Security typeOrdinary Share
Fiscal year-endApr 08
Address1050 Waltham Street, Suite 302
CityLEXINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02421
Phone16173146297
Websitehttps://www.kerostx.com/
Ticker SymbolKROS
IPO dateApr 08, 2020
CEOSeehra (Jasbir)
Company Executives of Keros Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jasbir Seehra, Ph.D.
Dr. Jasbir Seehra, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
392.72K
+29.94%
Mr. Julius Knowles
Mr. Julius Knowles
Independent Director
Independent Director
6.44K
+440.81%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Chairman of the Board
Independent Chairman of the Board
5.45K
+2625.00%
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Nima Farzan
Mr. Nima Farzan
Independent Director
Independent Director
5.25K
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Justin Frantz
Mr. Justin Frantz
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Keith C. Regnante
Mr. Keith C. Regnante
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Dr. Alpna Hansraj Seth, Ph.D.
Dr. Alpna Hansraj Seth, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lorena Lerner, Ph.D.
Dr. Lorena Lerner, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jasbir Seehra, Ph.D.
Dr. Jasbir Seehra, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
392.72K
+29.94%
Mr. Julius Knowles
Mr. Julius Knowles
Independent Director
Independent Director
6.44K
+440.81%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Chairman of the Board
Independent Chairman of the Board
5.45K
+2625.00%
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Nima Farzan
Mr. Nima Farzan
Independent Director
Independent Director
5.25K
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
5.25K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Nov 20
Updated: Thu, Nov 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Madison Avenue Partners LP
8.89%
The Vanguard Group, Inc.
8.89%
Tang Capital Management, LLC
7.94%
BlackRock Institutional Trust Company, N.A.
7.73%
Western Standard, LLC
7.19%
Other
59.37%
Shareholders
Shareholders
Proportion
Madison Avenue Partners LP
8.89%
The Vanguard Group, Inc.
8.89%
Tang Capital Management, LLC
7.94%
BlackRock Institutional Trust Company, N.A.
7.73%
Western Standard, LLC
7.19%
Other
59.37%
Shareholder Types
Shareholders
Proportion
Hedge Fund
44.98%
Investment Advisor
28.60%
Investment Advisor/Hedge Fund
23.28%
Research Firm
4.64%
Venture Capital
2.82%
Private Equity
2.64%
Corporation
1.89%
Individual Investor
1.79%
Pension Fund
1.13%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
385
41.03M
124.11%
-17.81M
2025Q2
392
46.16M
114.02%
-7.54M
2025Q1
394
39.41M
98.81%
-8.43M
2024Q4
366
43.10M
106.25%
-873.01K
2024Q3
351
43.05M
114.83%
+404.61K
2024Q2
337
39.69M
109.09%
-4.15M
2024Q1
332
39.81M
110.03%
+1.08M
2023Q4
310
34.40M
109.87%
-229.62K
2023Q3
303
31.04M
104.70%
-2.97M
2023Q2
305
30.88M
104.58%
-2.59M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Madison Avenue Partners LP
2.69M
6.63%
+77.06K
+2.95%
Jun 30, 2025
The Vanguard Group, Inc.
2.62M
6.45%
+53.89K
+2.10%
Jun 30, 2025
Tang Capital Management, LLC
1.42M
3.49%
+318.98K
+29.00%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.39M
5.88%
-118.03K
-4.71%
Jun 30, 2025
Western Standard, LLC
1.53M
3.78%
+1.40M
+1037.68%
Jun 30, 2025
D. E. Shaw & Co., L.P.
1.30M
3.19%
+34.25K
+2.71%
Jun 30, 2025
State Street Investment Management (US)
1.38M
3.41%
+81.72K
+6.27%
Jun 30, 2025
Nantahala Capital Management, LLC
1.62M
3.99%
+113.90K
+7.56%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.76%
ALPS Medical Breakthroughs ETF
0.26%
State Street SPDR S&P Biotech ETF
0.21%
Federated Hermes MDT Small Cap Core ETF
0.12%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
ProShares Ultra Nasdaq Biotechnology
0.09%
WisdomTree US SmallCap Quality Growth Fund
0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
iShares Biotechnology ETF
0.05%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.76%
ALPS Medical Breakthroughs ETF
Proportion0.26%
State Street SPDR S&P Biotech ETF
Proportion0.21%
Federated Hermes MDT Small Cap Core ETF
Proportion0.12%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.1%
ProShares Ultra Nasdaq Biotechnology
Proportion0.09%
WisdomTree US SmallCap Quality Growth Fund
Proportion0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.06%
Invesco Nasdaq Biotechnology ETF
Proportion0.06%
iShares Biotechnology ETF
Proportion0.05%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Keros Therapeutics Inc?
The top five shareholders of Keros Therapeutics Inc are:
Madison Avenue Partners LP holds 2.69M shares, accounting for 6.63% of the total shares.
The Vanguard Group, Inc. holds 2.62M shares, accounting for 6.45% of the total shares.
Tang Capital Management, LLC holds 1.42M shares, accounting for 3.49% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.39M shares, accounting for 5.88% of the total shares.
Western Standard, LLC holds 1.53M shares, accounting for 3.78% of the total shares.
Madison Avenue Partners LP holds 2.69M shares, accounting for 6.63% of the total shares.
The Vanguard Group, Inc. holds 2.62M shares, accounting for 6.45% of the total shares.
Tang Capital Management, LLC holds 1.42M shares, accounting for 3.49% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.39M shares, accounting for 5.88% of the total shares.
Western Standard, LLC holds 1.53M shares, accounting for 3.78% of the total shares.
What are the top three shareholder types of Keros Therapeutics Inc?
The top three shareholder types of Keros Therapeutics Inc are:
Madison Avenue Partners LP
The Vanguard Group, Inc.
Tang Capital Management, LLC
Madison Avenue Partners LP
The Vanguard Group, Inc.
Tang Capital Management, LLC
How many institutions hold shares of Keros Therapeutics Inc (KROS)?
As of 2025Q3, 385 institutions hold shares of Keros Therapeutics Inc, with a combined market value of approximately 41.03M, accounting for 124.11% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 10.09%.
What is the biggest source of revenue for Keros Therapeutics Inc?
In --, the -- business generated the highest revenue for Keros Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
